相关实验视频

Updated: Sep 13, 2025

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

杜尔佐胺和内塔苏迪尔对眼内压力和眼 perfusion 在早期玻璃眼的比较:一个随机对照试验

Vanaja Jain¹, Dewang Angmo¹, Gazella Bruce Warjri²

¹Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi - 110029, Delhi, India.

Journal of glaucoma

|July 28, 2025

概括

尼塔苏迪尔对早期青光眼患者有希望,改善了OCTA参数,并比多尔佐胺更能降低内血压. 这两种治疗方法的副作用率相似,这使得Netarsudil成为潜在的二线选择.

科学领域:

眼科医生眼科眼科
玻璃眼研究研究玻璃眼研究
医疗成像医学成像

背景情况:

玻璃眼是导致不可逆转失明的主要原因.
早期检测和干预对于治疗青光眼至关重要.
光学连贯断层扫描血管学 (OCTA) 提供了对眼球输液的新见解.

研究的目的:

为了比较Netarsudil和Dorzolamide对眼睛输液和视网膜神经纤维层在早期绿眼病的影响.
使用OCTA评估斑点和视神经头部 (ONH) perfusion 的变化.
通过OCT来评估斑点质细胞层 (mGCL) 和周状视网膜神经纤维层 (pRNFL) 厚度.

主要方法:

一个前性,随机的,主动控制的试验,对90个预周度/早期绿内障眼睛进行了研究.
患者接受了Netarsudil 0.02%或Dorzolamide 2%. 患者接受了Netarsudil 0.02%或Dorzolamide 2%. 患者接受了Netarsudil 0.02%或Dorzolamide 2%. 患者接受了Netarsudil 0.02%或Dorzolamide 2%.
主要结局包括通过OCTA测量眼内压力 (IOP),ONH输液,斑点血管密度 (mVD) 和ONH流量指数 (FI) 的变化,以及通过OCT测量12个月的pRNFL和mGCL厚度.

主要成果:

与多尔佐胺 (8.98±7.32%) 相比,尼塔苏迪尔显著降低了内脏压力 (13.23±8.27%).
尼塔苏迪尔增加了mVD (1.58 mm/mm2) 和ONH FI (7.6%),而多尔佐胺在这些参数中没有显著变化.
这两种药物都增加了ONH输液,副作用的比率相似 (内塔苏迪尔:拥堵;多佐胺:金属味道).

结论:

尼塔苏迪尔在改善OCTA参数 (mVD,ONH FI) 和IOP降低方面表现出优异的疗效,与早期青光眼的多尔佐胺相比.
尼塔苏迪尔是一种有前途的二线治疗选择,用于预先/早期的玻璃眼.
这两种治疗方法的安全性表现相似,这表明Netarsudil作为一种有效的治疗选择的潜力.

关键词:

多尔佐胺胺是什么意思在Netarsudil中使用.八国合作组织 (OCTA)在ONH流量指数上,流量指数在ONH perfusion中使用.早期的玻璃眼 glaucoma 的情况.斑点血管密度斑点血管密度预先测量的玻璃眼.预期随机对照试验预期随机对照试验

更多相关视频

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

相关概念视频

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...